|Table of Contents|

The application of 18F-FDG PET/CT imaging in the efficacy evaluation of multiple myeloma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4607-4610
Research Field:
Publishing date:

Info

Title:
The application of 18F-FDG PET/CT imaging in the efficacy evaluation of multiple myeloma
Author(s):
ZHAN Ying; WANG Zhiguo; HAO Shanhu; WU Xiaodan; ZHANG Guoxu
Department of Nuclear Medicine,General Hospital of Northern Theater Command,Liaoning Shenyang 110016,China.
Keywords:
multiple myeloma; PET/CT; efficacy assessment; 18F-FDG
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2023.24.023
Abstract:
Objective:To investigate the role of 18F-FDG PET/CT imaging in the evaluation of the efficacy of multiple myeloma.Methods:A retrospective analysis of 28 patients with multiple myeloma,17 males and 11 females,with an average age of (56.3±0.4) years old,who underwent 18F-FDG PET/CT examination in our hospital from January 2017 to December 2020 was performed.The characteristics of radioactivity distribution before and after treatment were analyzed by two nuclear medicine specialists,and the efficacy of the patients was evaluated by clinicians.SPSS 18.0 statistical software was used for analysis,and the t-test for independent samples was used for measurement data,and the χ2 test was used for comparison of count data.Results:In the 28 patients,10 patients (35.7%) had CR,3 patients (10.7%) with VGPR,5 patients (17.9%) with PR,7 patients (25.0%) with SD,and 3 patients (10.7%) with PD.The overall treatment remission rate was 64.3%.The SUVmax values of multiple myeloma patients who achieved CR and PR after treatment decreased significantly compared with those before treatment,and the difference was statistically significant (P＜0.05).The SUVmax values of patients who achieved VGPR and SD after treatment decreased compared with those before treatment,and the SUVmax value of patients who achieved PD after treatment increased compared with those before treatment,but the differences were not statistically significant (P>0.05).After CR treatment,the number of patients with the number of active lesions >3 decreased significantly,but the difference was not statistically significant (P＞0.05).Conclusion:18F-FDG PET/CT has an important role in assessing the efficacy of multiple myeloma and provides a reliable clinical basis.

References:

[1] CAERS J.The road to a cure:emerging treatments for multiple myeloma［J］.Cancers (Basel),2020,12(12):3593.
[2] WANG S,XU L,FENG J,et al.Prevalence and incidence of multiple myeloma in urban area in China:a national population-based analysis［J］.Frontiers in Oncology,2020,9:1513.
[3] SILBERSTEIN J,TUCHMAN S,GRANT SJ.What is multiple myeloma［J］.JAMA,2022,327(5):497.
[4] COWAN AJ,GREEN DJ,KWOK M,et al.Diagnosis and management of multiple myeloma:a review［J］.JAMA,2022,327(5):464-477.
[5] NASSAR S,TAHER A,SPEAR R,et al.Multiple myeloma:role of imaging in diagnosis,staging,and treatment response assessment［J］.Semin Ultrasound CT MR,2021,42(2):184-193.
[6] RAJKUMAR SV,DIMOPOULOS MA,PALUMBO A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma［J］.Lancet Oncol,2014,15(12):e538-e548.
[7]中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)［J］.中华内科杂志,2015,54(12):1066-1070. Chinese Hematology Association,Chinese Society of Hematology,Chinese Myeloma Committee-Chinese Hematology Association.The guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)［J］.Chinese Journal of Internal Medicine,2015,54(12):1066-1070.
[8] HINGE M,ANDERSEN KT,LUND T,et al.Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray,low-dose computed tomography,and 18flourodeoxyglucose positron emission tomography in previously untreated patients［J］.Haematologica,2016,101(10):415-418.
[9] FIRTH J.Haematology:multiple myeloma［J］.Clin Med (Lond),2019,19(1):58-60.
[10] TAGLIAFICO AS,DOMINIETTO A,BELGIOIA L,et al.Quantitative imaging and radiomics in multiple myeloma:a potential opportunity［J］.Medicina (Kaunas),2021,57(2):94.
[11] TERAO T,MATSUE K.Progress of modern imaging modalities in multiple myeloma［J］.Int J Hematol,2022,115(6):778-789.
[12] 郝珊瑚,张国旭,王治国,等.18F-FDG PET/CT显像对多发性骨髓瘤诊断效能的回顾性研究［J］.现代肿瘤医学,2014,22(4):903-906. HAO SH,ZHANG GX,WANG ZG,et al.The diagnostic accuracy of 18F-FDG PET/CT imaging in multiple myeloma-a retrospective study［J］.Modern Oncology,2014,22(4):903-906.
[13] ZAMAGNI E,PATRIARCA F,NANNI C,et al.Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation［J］.Blood,2011,118(23):5989-5995.
[14] LI Y,LIU J,HUANG B,et al.Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma［J］.Oncotarget,2017,8(15):25637-25649.
[15] BASHA MAA,HAMED MAG,REFAAT R,et al.Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma:a prospective comparative study［J］.Jpn J Radiol,2018,36(6):382-393.
[16] DERLIN T,PELDSCHUS K,MNSTER S,et al.Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation［J］.Eur Radiol,2013,23(2):570-578.
[17] ANTJE STOLZENBURG,KATHARINA LUECKERATH,SAMUEL SAMNICK,et al.Prognostic value of［18F］FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation［J］.Eur J Nucl Med Mol Imaging,2018,45(10):1694-1704.
[18] HAN S,WOO S,KIM YI,et al.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma:a systematic review and meta-analysis［J］.Eur Radiol,2021,31(1):152-162.
[19] KIM SJ,YI HK,LIM CH,et al.Intra-patient variability of FDG standardized uptake values in mediastinal blood pool,liver,and myocardium during R-CHOP chemotherapy in patients with diffuse large B-cell lymphoma［J］.Nucl Med Mol Imaging,2016,50:300-307.
[20] PARK S,LEE SJ,CHANG WJ,et al.Positive correlation betweenbaseline PET or PET/CT findings and clinical parameters in multle myeloma patients［J］.Acta Haematol,2014,131(4):193-199.
[21] BARTEL TB,HAESSLER J,BROWN TL,et al.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma［J］.Blood,2009,114:2068-2076.
[22] 吴增杰,边甜甜,王艳丽,等.18F-FDG PET／CT显像SUVmax＞2.5的病灶数及肿瘤代谢体积对多发性骨髓瘤预后评估的价值［J］.中华核医学与分子影像杂志,2016,36(1):44-47. WU ZJ,BIAN TT,WANG YL,et al.Prognostic value of the number of lesions with SUVmax>2.5 and metabolic tumor volume assessed by 18F-FDG PET/CT imaging in patients with multiple myeloma［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2016,36(1):44-47.

Memo

Memo:
-
Last Update: 1900-01-01